The Small Antitumoral Immune Response Modifier Imiquimod Interacts with Adenosine Receptor Signaling in a TLR7- and TLR8-Independent Fashion
- 1 June 2006
- journal article
- Published by Elsevier BV in Journal of Investigative Dermatology
- Vol. 126 (6), 1338-1347
- https://doi.org/10.1038/sj.jid.5700286
Abstract
No abstract availableThis publication has 43 references indexed in Scilit:
- Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle-controlled phase III study in EuropeBritish Journal of Dermatology, 2005
- Viral and Nonviral Uses of Imiquimod: A ReviewJournal of Cutaneous Medicine and Surgery, 2004
- Imiquimod Treatment Induces Expression of Opioid Growth Factor ReceptorClinical Cancer Research, 2004
- Adenosine A2A or A3 receptors are required for inhibition of inflammation by methotrexate and its analog MX‐68Arthritis & Rheumatism, 2003
- Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848Nature Immunology, 2002
- Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damageNature, 2001
- The Imidazoquinolines, Imiquimod and R-848, Induce Functional, but Not Phenotypic, Maturation of Human Epidermal Langerhans' CellsClinical Immunology, 2000
- Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% creamJournal of the American Academy of Dermatology, 1999
- Glycoprotein P3.58, associated with tumor progression in malignant melanoma, is a novel leukocyte activation antigenInternational Journal of Cancer, 1988
- Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line.The Journal of cell biology, 1988